Humacyte Aktie News

Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at com...

DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency.

Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M annual revenue opportunity, depending on market penetration and future FDA approvals for expanded indications. Financial risks remain due to high cash burn and potential dilution, but current valua...

DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients at high risk of aut...

DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for high-risk patients with end-stage r...

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.

Humacyte, Inc. (NASDAQ:HUMA ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Founder, President and Chief Executive Officer Dale Sander - Chief Financial Officer, Chief Corporate Development Officer and Treasurer BJ Scheessele - Chief Commercial Officer Conference Call Partic...

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -